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C-Reactive Protein and Annexin A5 Bind to Distinct Sites of
Negatively Charged Phospholipids Present in Oxidized
Low-Density Lipoprotein
Lambertus van Tits, Jacqueline de Graaf, Helga Toenhake, Waander van Heerde, Anton Stalenhoef
Objective—To investigate binding of C-reactive protein (CRP) and annexin A5, 2 proteins with high affinity for negatively
charged phospholipids, to oxidized low-density lipoprotein (LDL) and the consequences of these interactions for
subsequent binding of oxidized LDL to monocyte/macrophage-like U937 cells.
Methods and Results—We found that CRP and annexin A5 at physiological concentrations bind Ca dependently to
oxidized phosphatidylcholine present in oxidized LDL but not to native LDL. Binding of CRP to oxidized LDL did not
interfere with binding of annexin A5, and vice versa. In the presence of 2 to 10 mg/L CRP, binding of 125I-labeled
oxidized LDL to undifferentiated U937 cells increased 50% to 100%. This effect was independent of the presence of
complement and could be inhibited by irrelevant IgG and by antibodies to CD64 but not by annexin A5. Annexin A5
alone had no effect on binding of oxidized LDL to the cells.
Conclusions—These findings suggest that: (1) CRP and annexin A5 at physiological concentrations bind to distinct sites
of negatively charged phospholipids present in oxidized LDL; (2) CRP enhances binding of oxidized LDL to
monocytic/macrophage-like cells via Fc receptors; and (3) annexin A5 does not antagonize the CRP-induced enhanced
binding of oxidized LDL to U937 cells. (Arterioscler Thromb Vasc Biol. 2005;25:717-722.)
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High-sensitivity C-reactive protein (CRP) in the normalrange (1 to 10 mg/L) measured by highly sensitive
assays, is a strong risk factor for future cardiovascular
events.1,2 This reflects the concept of atherosclerosis as a
low-grade inflammatory state. It has been demonstrated that
CRP can be synthesized by macrophages and smooth mus-
cle–like cells present in human atherosclerotic plaques.3,4
This suggests that small amounts of CRP may be continu-
ously released from advanced atheromatous tissue and per-
sistent increases in serum CRP may reflect a stage of
atherosclerosis more likely to lead to acute thrombotic events.
Whether the relationship of CRP with cardiovascular
disease is causal is still a matter of debate. It has been
demonstrated that CRP has direct pro-inflammatory effects
on human endothelial cells in vitro while synchronously
attenuating the biosynthesis of nitric oxide.5,6 Furthermore,
CRP may influence the formation of foam cells in atheroscle-
rotic lesions. Antibodies directed to the phosphorylcholine
units of negatively charged phospholipids, which are present
in much higher amounts in oxidized low-density lipoprotein
(LDL) than in native LDL,7 block the binding and uptake of
oxidized LDL via scavenger receptors into macrophages.
CRP might have a similar inhibitory effect on macrophage
uptake of oxidized LDL via scavenger receptors because it
binds to the same epitope on oxidized LDL as do the natural
antibodies to oxidized LDL.7–11 However, macrophage up-
take of CRP–LDL complexes might be increased by subse-
quent binding of CRP to Fc receptors.12,13 In addition,
binding of CRP to oxidized LDL and degraded nonoxidized
LDL transforms the acute-phase protein to an activator of the
classical complement pathway.14 This opsonization may fur-
ther increase macrophage uptake of the complexes by binding
to complement receptors. Overactivation of these pathways,
eg, by excessive LDL deposition and/or enhanced CRP
production, might result in chronic inflammation promoting
plaque progression and destabilization.
Annexin A5 is an intracellular protein that is abundantly
present in endothelial cells and platelets, and which exhibits
a high affinity for anionic phospholipids in membranes.15 On
release, it exhibits anticoagulant/antithrombotic and anti-
inflammatory properties by covering the negatively charged
moieties of the phospholipid head group.16,17 In healthy, lean
individuals, annexin A5 circulates at low concentrations in
plasma (0.03 to 0.15 nmol/L, ie, 1 to 5 ng/mL). Increased
plasma levels of annexin A5 were observed in patients with
acute myocardial infarction or unstable angina,18 and abun-
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dant expression is observed in atherosclerotic lesions of
coronary arteries.19 Because of its high affinity for anionic
phospholipids, similar to CRP, annexin A5 might have an
inhibitory effect on macrophage uptake of oxidized LDL via
scavenger receptors. It is not known whether annexin A5
binds to LDL and/or interferes with binding of CRP to LDL.
Association of annexin A5 with lipoproteins in vivo is
difficult to demonstrate. Still, in view of the rather opposite
conditions annexin A5 and CRP are associated with, such an
interaction could be of clinical relevance. In the present
study, we investigated binding of CRP and annexin A5 to
native and oxidized LDL and its consequences for binding of
LDL to monocyte/macrophage-like U937 cells.
Materials and Methods
Human LDL was prepared and modified as described.20 Apolipopro-
tein B (apoB) molecules of oxidatively modified LDL contained, on
average, 48 substituted lysines, an amount that is nearly sufficient to
enable the interaction of LDL with the scavenger receptor,21 and thus
is considered minimally modified. Anti-human apoB-100 polyclonal
antibodies were raised in a goat; the antibody is used for routine
immunonephelometric measurement of apoB-100 and was shown to
recognize apoB of oxidized LDL, too.20 Recombinant human CRP
(Escherichia coli) was obtained from Calbiochem (San Diego,
Calif), stabilized human serum containing 90 to 100 mg/L CRP was
from Roche (Mannheim, Germany; calibrator for automated sys-
tems), and recombinant annexin A5 was obtained as described.22
Monoclonal antibody 4E6 (murine IgG), directed to a conforma-
tional epitope in the apoB-100 moiety of LDL that is generated as a
consequence of aldehyde substitution of lysine residues,23 was
purchased from Mercodia (Mercodia, Uppsala, Sweden); anti-
oxidized phosphatidylcholine monoclonal antibody DLH3 (murine
IgM)24 was a gift from Dr H. Itabe (Teikyo University, Kanagawa,
Japan). The monoclonal antibodies FUN-2 (mouse IgG, anti-human
CD32) and 10.1 (mouse IgG, anti-human CD64) were obtained from
BioLegend (San Diego, Calif).
Enzyme-Linked Immunosorbent Assay for CRP
and Annexin A5 Binding to Antigens
Binding of CRP and annexin A5 to LDL was determined by using an
enzyme-linked immunosorbent assay. Native or oxidized LDL (0.5
g/well) were captured by anti-human apoB-100 polyclonal anti-
bodies coated on microtiter wells (8 g/mL, 100 L/well, in
phosphate-buffered saline [PBS]). In some experiments, LDL was
coated directly onto the wells of a microtiter plate in the presence of
0.25 mmol/L ethylenediaminetetra-acetate (EDTA) and 20 mol/L
butyl-hydroxytoluene. Antigens in the wells were blocked with 1%
bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, Mo; cata-
logue number A-7030) in PBS and then incubated with CRP and/or
annexin A5 (diluted in 10 mmol/L Tris/2 mmol/L CaCl2/1 mmol/L
MgCl2/1% BSA, pH 7.4, incubation buffer) for 90 minutes at room
temperature. If binding was to be performed in absence of calcium,
CaCl2 was omitted and EDTA (10 mmol/L) added to the incubation
buffer. After washing with PBS containing 0.05% tween-20, bound
CRP was detected by incubation with peroxidase-conjugated rabbit
anti-human CRP antibodies (Dako, Glostrup, Denmark), or bound
annexin A5 was detected by incubating subsequently with rabbit
anti-annexin A5 polyclonal antibodies (Hyphen Biomed, Andresy,
France) and peroxidase-conjugated swine anti-rabbit antibodies
(Dako, Glostrup, Denmark), all diluted in incubation buffer. After
further washes, peroxidase activity was initiated using tetramethyl-
benzidine as a substrate and terminated by addition of 2 mol/L
H2SO4. Bound CRP and annexin A5 are expressed in absorption
units.
Iodination of Oxidized LDL With 125I
Iodination of oxidized LDL was performed using the chloramine-T
procedure. Briefly, 0.5 mCi Na125I (Amersham Cygne, Eindhoven,
the Netherlands) and chloramine-T (1.4 mmol/L final concentration)
were added to 0.5 mg oxidized LDL protein in 0.25 mL PBS pH 7.4,
gently mixed, and incubated for 1 minute at room temperature.
Iodination was stopped by addition of sodium metabisulfite
(3.3 mmol/L final concentration) and free iodine was removed by
sephadex G-25 mol/L gel filtration (PD-10 columns; Pharmacia
Biosciences, Uppsala, Sweden). The 125I-labeled oxidized LDL peak
was collected in PBS. Specific radioactivity amounted to 800 000
cpm/g protein. More than 90% of the radioactivity was precipitable
by 10% trichloracetic acid.
Binding of Oxidized LDL to U937 Cells
The monocyte/macrophage-like U937 cell line25 was used to assess
binding of oxidized LDL to cells. U937 cells were grown (3 to
8105 cells/mL) in RPMI1640 medium (GIBCO BRL, Glasgow,
Scotland) supplemented with 10% heat-inactivated fetal calf serum
in a humidified 5% CO2 atmosphere at 37°C. For binding studies,
1106 cells were incubated for 3 hours at 4°C with 50 ng 125I-labeled
oxidized LDL in the presence and absence of 1 g nonlabeled
oxidized LDL in 1 mL CO2-independent medium (GIBCO BRL,
Glasgow, Scotland) supplemented with 10% fetal calf serum and
2 mmol/L L-glutamine. The cells were gently stirred every hour.
After incubation cells were washed 3 times in ice-cold PBS contain-
ing 0.05% tween-20, radioactivity of the cell pellet was determined.
Statistical Analysis
All measurements were performed at least in duplicate and each
experiment was performed 3 to 5 times. Data are presented as
meansSD. Student t test was used for evaluation.
Results
CRP Binding to LDL
First, we evaluated binding of CRP to LDL captured by
anti-human apoB-100 polyclonal antibodies coated on micro-
titer wells. As checked by detection of apoB-100, equal
amounts of native and oxidized LDL were coated onto the
wells (not shown). CRP bound to oxidized LDL but not to
native LDL (Figure 1, left). Identical results were obtained
with recombinant human CRP and CRP from stabilized
human serum. Binding of CRP to oxidized LDL was
monophasic and saturable; EC50 amounted to 0.2 mg/L CRP
and a plateau was reached at 2 mg/L CRP. Binding of CRP
to oxidized LDL was dependent on the presence of calcium in
the medium because in the absence of calcium, no binding of
CRP to oxidized LDL was observed. By increasing the
concentration of BSA in the incubation buffer, binding of
Figure 1. Binding of CRP (left) and annexin A5 (right) to native
(diamonds) and oxidized LDL (triangles) in the absence (open
symbols) and presence (filled symbols) of calcium in the
medium. Anx A5 indicates annexin A5CRP; CRP, C-reactive
protein.
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CRP was reduced (not shown); at physiological concentration
of albumin (4 to 4.5 g/L), 70% to 77% of CRP binding
remained present. When the LDL was coated directly onto the
wells of a microtiter plate, CRP bound to both native and
oxidized LDL, but plateau levels for oxidized LDL were
2-fold to 3-fold higher (not shown). In the absence of LDL
(ie, when wells were blocked with BSA only), no binding of
CRP was observed.
Annexin A5 Binding to LDL
We observed a strong binding of annexin A5 to the captured
oxidized LDL but not to captured native LDL (Figure 1,
right). Binding of annexin A5 to oxidized LDL was
monophasic and saturable; EC50 amounted to 0.05 nmol/L
annexin A5 and a plateau was reached at 1 nmol/L annexin
A5 and remained unchanged until at least 300 nmol/L (not
shown). In the absence of calcium, no binding of annexin A5
to oxidized LDL was observed. Increasing the concentration
of BSA in the medium up to 5% (wt/vol) did not influence
binding of annexin A5. In the absence of LDL (ie, when wells
were blocked with BSA only), no binding of annexin A5 was
observed.
Monoclonal Antibody DLH3 Inhibits CRP and
Annexin A5 Binding to Oxidized LDL
Both monoclonal antibodies DLH3 and 4E6 recognize oxi-
dized LDL. However, they are directed to different epitopes
of the particle; 4E6 recognizes a conformational epitope in
the apoB100 of LDL that is generated as a consequence of
aldehyde substitution of lysine residues;23 DLH3 is directed
to an epitope of oxidized phosphatidylcholine.24 To get more
insight into the binding sites of CRP and annexin A5 on
oxidized LDL, we tested whether these monoclonal antibod-
ies and polyclonal antibodies to apoB can compete with CRP
and annexin A5 for binding to oxidized LDL (Figure 2).
Pre-incubation of captured oxidized LDL with DLH3 for 10
minutes successfully competed for70% of binding of CRP;
in contrast, monoclonal antibody 4E6 prevented only 25%
of binding of CRP. Similarly, binding of annexin A5 to
captured oxidized LDL was reduced by pre-incubation with
DLH3 but not affected by pre-incubation with 4E6. However,
for inhibition of annexin A5 binding to oxidized LDL, higher
molar ratio of DLH3/competitor was needed than for inhibi-
tion of CRP binding to oxidized LDL. Pre-incubation with
polyclonal antibodies to apoB had no effect on subsequent
binding of CRP and annexin A5 to captured oxidized LDL
(not shown).
Annexin A5 Does Not Interfere With CRP Binding
to Oxidized LDL, and Vice Versa
The findings that pre-incubation of oxidized LDL with the
monoclonal antibody DLH3 reduces subsequent binding of
both CRP and of annexin A5 to oxidized LDL suggests that
both compounds bind to oxidized phosphatidylcholine pres-
ent in oxidized LDL. To test competition between CRP and
annexin A5 for binding to oxidized LDL, we incubated
oxidized LDL subsequently with annexin A5 and CRP (each
1 hour), or vice versa, and determined CRP and annexin A5
present on the LDL. In addition, we determined CRP and
annexin A5 bound to oxidized LDL after incubation of
oxidized LDL with a mixture of both proteins (for 1.5 hours).
Using this experimental set-up, we found that annexin A5
(either present in the incubation mixture or already bound to
oxidized LDL as a result of pre-incubation) did not disturb
binding of CRP to oxidized LDL (Figure 3, left). Conversely,
CRP present in the incubation mixture or bound to oxidized
LDL as a result of pre-incubation only slightly reduced
binding of annexin A5 to oxidized LDL (Figure 3, right).
Furthermore, it was observed that annexin A5 did not
displace CRP from oxidized LDL, nor did CRP displace
annexin A5 (not shown).
Figure 2. Inhibition of CRP (1.3 mg/L, upper panel) and annexin
A5 (0.9 nmol/L, lower panel) binding to oxidized low-density
lipoprotein by the monoclonal antibodies DLH3 (diamonds) and
4E6 (squares).
Figure 3. Binding curves of CRP (left) and annexin A5 (right) to
oxidized low-density lipoprotein pre-incubated with annexin A5
(3 nmol/L, squares, left) or CRP (10 mg/L, squares, right) or
control (diamonds).
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CRP Stimulates Binding of Oxidized LDL to
U937 Cells
After incubation of undifferentiated U937 cells at 4°C with
125I-labeled oxidized LDL, cell-associated radioactivity max-
imally amounted to 20% of added 125I-labeled oxidized LDL.
Approximately 62% to 91% of cell-associated radioactivity
appeared to be specific because nonspecific values, deter-
mined by incubating cells with a 20-fold excess of nonlabeled
oxidized LDL, maximally amounted to 38% of cell-
associated radioactivity.
To assess the influence of CRP and annexin A5 on cellular
binding of oxidized LDL, U937 cells were incubated with
125I-labeled oxidized LDL in the presence and absence of
different concentrations of CRP and annexin A5. Annexin A5
at 1 and 5 nmol/L did not influence total or nonspecific
cell-associated radioactivity (not shown); however, in the
presence of 2 to 10 mg/L CRP, mean total cell-associated
radioactivity was 35% higher. Because nonspecific values
were minimally influenced by CRP, the increase in total
cell-associated radioactivity was the result of a mean 30% to
55% increase in specific binding of oxidized LDL to the cells
(Figure 4). Heat-inactivation of fetal calf serum for 1 hour at
56°C did not change the stimulatory effect of CRP on binding
of oxidized LDL to U937 cells (Figure 4), nor did coincuba-
tion with annexin A5 (data not shown). However, increasing
amounts of irrelevant IgG markedly reduced the stimulatory
effect of CRP on binding of oxidized LDL to U937 cells
(Figure 5). Furthermore, at much lower concentrations,
monoclonal antibodies to CD64 (FcRI) also inhibited the
effect of CRP; at 20 g/mL, 80% of CRP-induced increase in
binding of oxidized LDL to U937 cells was prevented (not
shown), whereas an irrelevant IgG antibody at that concen-
tration had barely any effect (Figure 5). Monoclonal antibod-
ies to CD32 (FcRII) showed inconsistent results, inhibiting
the CRP effect from 0% to 50% (not shown).
Discussion
In the present study, we show that both CRP and annexin A5
specifically bind to oxidized LDL. Via coupling to Fc
receptors on macrophages and independent of complement,
CRP subsequently enhances the association of oxidized LDL
to macrophages. Enhanced association of oxidized LDL to
macrophages via CRP–Fc receptor interaction may lead to
enhanced macrophage uptake of oxidized LDL. Moreover,
we show that annexin A5 binds to a site at oxidized LDL
different from the CRP binding site and that annexin A5 does
not antagonize the CRP effect.
Previously, Chang et al also observed specific binding of
CRP to oxidized LDL,7 characterized by inhibition by whole
molecules as well as F(ab)2 fragments of EO6, an IgM
antibody that binds specifically to the phosphorylcholine
head group of oxidized phospholipids but not to the same
moiety on nonoxidized phospholipids.26 In the present study,
for characterization of binding sites, we used the monoclonal
antibody DLH3 (also IgM), which recognizes an epitope of
the choline head group of oxidized phosphatidylcholine,27
and 4E6, an IgG antibody that is directed to a conformational
epitope in the apoB-100 moiety of LDL that is generated as
a consequence of aldehyde substitution of the lysine residues
of apoB-100.23 We found that DLH3, but not 4E6 and
polyclonal antibodies to apoB, effectively competes with
CRP and annexin binding to oxidized LDL, suggesting that
both ligands bind to the choline head group of oxidized
phospholipids present in the LDL and that specific sequences
of the apoB were not essential. Furthermore, the binding was
calcium-dependent and, most importantly, occurred at phys-
iological concentrations, ie, for CRP at 0.1 to 2 mg/L and for
annexin A5 at 0.01 to 0.5 nmol/L.
Similar to Chang et al,7 we also observed binding of CRP
to native LDL adsorbed on the plastic of microtiter wells,
despite the presence of antioxidants, but not to native LDL
captured by anti-human apoB-100 polyclonal antibodies
coated on the wells. Like Chang et al, we believe that by
adhering on the well, the native configuration of LDL is
altered in a way similar to that resulting from oxidation,
leading to exposure of the phosphatidylcholine moiety. This
hypothesis is supported by the finding that next to oxidized
LDL, enzymatically modified LDL14 and aggregated LDL,
but not monomeric native LDL,7 also bind CRP. Zwaka et
al13 previously observed CRP-mediated uptake of native LDL
by macrophages. However, they used LDL from a commer-
cial source, and slight alterations of the natural configuration
and/or minimal oxidation may have led to binding of CRP to
native LDL.
Figure 4. Effect of CRP on binding of oxidized LDL to U937
cells in the presence of 10% fetal calf serum (control) or 10%
heat-inactivated fetal calf serum. Changes in binding of oxidized
LDL to U937 cells are given in percent of control. FCS indicates
fetal calf serum; oxLDL, oxidized low-density lipoprotein.
Figure 5. Effect of IgG on CRP-induced enhanced binding of
oxidized LDL to U937 cells. IgG indicates immunoglobulin G
720 Arterioscler Thromb Vasc Biol. April 2005
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Although activation of complement did not seem to be
involved in CRP-mediated enhanced association of oxidized
LDL to macrophages, inhibition through relatively high
concentrations of IgG, and specifically through monoclonal
antibodies to CD64 at lower concentrations, suggests involve-
ment of FcRI. Recently Bodman-Smith et al12 showed that
phospholipase D activation of (interferon-–treated) U937
cells in response to CRP is mediated by FcRI (CD64),
indicating that FcRI is involved in the interaction of CRP
with U937 cells. Zwaka et al,13 using circulating monocytes
that were transformed into macrophages, suggested a role for
FcRII (CD32) in CRP-mediated uptake of native LDL,
whereas Fu and Borensztajn28 observed that uptake by U937
macrophages of complexes of aggregated CRP and LDL was
CD32-independent. In the present study, we cannot exclude
involvement of FcRII in interaction of CRP with U937 cells,
because the data with antibodies to CD32 were inconsistent.
The reason for this is not clear. Moreover, we only studied
association and did not investigate whether the interaction of
CRP-oxidized LDL complexes with Fc receptors leads to
uptake of the complexes by the cells or which interaction is
required for uptake. Extensive research with fluorescence-
labeled lipoproteins is necessary to establish this.
The interaction of CRP with oxidized LDL and Fc
receptors may lead to elimination of the lipoprotein particle.
Another route of LDL clearance is the scavenger receptor
pathway. In the absence of anti-oxidized LDL antibodies and
opsonizing agents, oxidized LDL binds to scavenger recep-
tors present on phagocytic cells. Chang et al recently showed
that, like autoantibodies to oxidized LDL, CRP directly
inhibits the binding of oxidized LDL to scavenger receptors.29
Although in that study, CD36-transfected cells (COS-7) and
high concentrations of CRP (up to 150 mg/L) were used, their
findings fit with our data. In our study, we did not assess
specific binding to scavenger receptors and we did not
analyze scavenger receptors on U937 cells; however, we do
show that DLH3 (which is an IgM monoclonal antibody
comparable to E06, the prototypic IgM autoantibody to
oxidized LDL) and CRP compete for the same binding site on
oxidized LDL. Moreover, we observed that in the presence of
CRP and irrelevant IgG, binding of oxidized LDL to U937
cells decreases to levels below control (ie, in the absence of
CRP and IgG). In our opinion, this results from blockade of
oxidized LDL-binding to scavenger receptors by CRP in
addition to inhibition of CRP–Fc receptor interaction by
irrelevant IgG. In the absence of CRP, oxidized LDL binds to
scavenger receptors; in the presence of CRP, binding of
oxidized LDL represents mainly CRP–Fc receptor interac-
tion. This suggests that CRP influences the route of oxidized
LDL processing by mediating oxidized LDL–Fc receptor
interaction and inhibiting binding of oxidized LDL to scav-
enger receptors. This may be a very important mechanism
determining the rate of atherogenesis. Although we did not
perform LDL uptake studies, we believe that it is reasonable
to assume that enhanced association of oxidized LDL to
macrophages via CRP–Fc receptor interaction leads to
enhanced uptake of oxidized LDL by these cells. At moderate
LDL deposition, these actions of CRP will then contribute to
rapid clearance of oxidized LDL; however, at excessive LDL
deposition (eg, caused by elevated plasma LDL cholesterol
levels), this mechanism might promote foam cell formation
and accelerate atherosclerosis. In favor of this, several studies
have demonstrated the presence of CRP in atherosclerotic
lesions of human aortas, localized around foam cells and the
deep fibro-elastic layer and the fibromuscular layer adjacent
to the media.30–32
Annexin A5 is well-known to bind to negatively charged
phospholipids present in lipid membranes, a property that
underlies its anticoagulant and anti-inflammatory activities
and that makes it a suitable tool to study apoptosis.33,34
However, association of annexin A5 to lipoproteins has not
been demonstrated before. For our experiments, we isolated
LDL from plasma and modified it in vitro. It would be
interesting to investigate whether in vivo circulating LDL and
LDL retained subendothelially at sites of atherosclerosis
contains annexin A5. Because annexin A5 does not interfere
with binding of CRP to oxidized LDL, it may not influence
effects resulting from CRP–LDL interaction. However, an-
nexin A5 may directly inhibit the procoagulant and pro-
inflammatory activities of oxidized LDL. Oxidized phospho-
lipids generated during oxidative modification of LDL have
been shown to exert a wide variety of atherogenic effects on
all cell types involved in atherosclerosis,35 but the modes by
which these actions are accomplished are obscure. Biological
testing of different oxidized phospholipids in combination
with annexin A5 may give more insight into the specific
receptors that are proposed to exist for the phospholipids.
Furthermore, although in the present study no indications
were found for an effect of annexin A5 on binding of oxidized
LDL to scavenger receptors, this needs to be investigated
thoroughly using transfected cells.
In conclusion, CRP binds specifically to oxidized LDL and
thus influences the route of oxidized LDL processing by
enabling interaction of the complex with Fc receptors on
phagocytic cells. Annexin A5 also binds specifically to
oxidized LDL, but at a site different from CRP.
Acknowledgments
This work was supported by a grant from the Netherlands Heart
Foundation (2001.137).
References
1. Koenig W, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G,
Hombach V, Marz W, Pepys MB, Brenner H. Infection with Helicobacter
pylori is not a major independent risk factor for stable coronary heart
disease: lack of a role of cytotoxin- associated protein A-positive strains
and absence of a systemic inflammatory response. Circulation. 1999;100:
2326–2331.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N Engl J Med. 1997;336:973–979.
3. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of
C-reactive protein and complement components in atherosclerotic
plaques. Am J Pathol. 2001;158:1039–1051.
4. Ishikawa T, Imamura T, Hatakeyama K, Date H, Nagoshi T, Kawamoto
R, Onitsuka H, Matsuyama A, Matsuo T, Asada Y, Eto T. Production of
C-reactive protein in the coronary plaque and release into coronary
circulation. Circulation 2002;106(19Suppl II):346. Abstract.
5. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of
C-reactive protein on human endothelial cells. Circulation. 2000;102:
2165–2168.
6. Verma S, Li S-H, Badiwala MV, Wiesel RD, Mickle DAG, Stewart DJ.
Unravelling the mechanistic basis of the CRP-atherosclerosis connection:
van Tits et al CRP and Annexin A5 Binding to LDL 721
 at Radboud Universiteit Nijmegen on December 4, 2012http://atvb.ahajournals.org/Downloaded from 
novel role of nitric oxide and endothelin-1. Circulation 2002;
106(19Suppl II):249. Abstract.
7. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein
binds to both oxidized LDL and apoptotic cells through recognition of a
common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl
Acad Sci U S A. 2002;99:13043–13048.
8. Thompson D, Pepys MB, Wood SP. The physiological structure of human
C-reactive protein and its complex with phosphocholine. Structure Fold
Des. 1999;7:169–177.
9. de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB.
Low density lipoprotein and very low density lipoprotein are selectively
bound by aggregated C-reactive protein. J Exp Med. 1982;156:230–242.
10. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and
lipoproteins. Int Rev Exp Pathol. 1985;27:83–111.
11. Rowe IF, Soutar AK, Trayner IM, Baltz ML, de Beer FC, Walker L,
Bowyer D, Herbert J, Feinstein A, Pepys MB. Rabbit and rat C-reactive
proteins bind apolipoprotein B-containing lipoproteins. J Exp Med. 1984;
159:604–616.
12. Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM,
Raynes JG. C-reactive protein-mediated phagocytosis and phospholipase
D signalling through the high-affinity receptor for immunoglobulin G (Fc
gamma RI). Immunology. 2002;107:252–260.
13. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low
density lipoprotein uptake by macrophages: implications for atheroscle-
rosis. Circulation. 2001;103:1194–1197.
14. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and
atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances
complement activation. Arterioscler Thromb Vasc Biol. 1999;19:
2348–2354.
15. Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens
WT, Willems GM. Binding of vascular anticoagulant alpha (VAC alpha)
to planar phospholipid bilayers. J Biol Chem. 1990;265:4923–4928.
16. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial
purification of a novel anticoagulant from arteries of human umbilical
cord. Eur J Biochem. 1985;151:625–629.
17. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recom-
binant annexin V in a rabbit carotid artery injury model. Circulation.
1997;96:2339–2347.
18. Kaneko N, Matsuda R, Hosoda S, Kajita T, Ohta Y. Measurement of
plasma annexin V by ELISA in the early detection of acute myocardial
infarction. Clin Chim Acta. 1996;251:65–80.
19. van Heerde WL, Lap P, Schoormans S, de Groot PG, Reutelingsperger C,
Vroom T. Localization of annexin A5 in human tissues. Annexins. 2004;
1:e56–e62.
20. Van Tits L, de Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet
P, Stalenhoef A. Increased levels of low-density lipoprotein oxidation in
patients with familial hypercholesterolemia and in end-stage renal disease
patients on hemodialysis. Lab Invest. 2003;83:13–21.
21. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-
mediated recognition of malondialdehyde-modified low density
lipoproteins. Proc Natl Acad Sci U S A. 1982;79:1712–1716.
22. van Heerde WL, Reutelingsperger CP, Maassen C, Lux P, Derksen RH,
de Groot PG. The presence of antiphospholipid antibodies is not related
to increased levels of annexin A5 in plasma. J Thromb Haemost. 2003;
1:532–536.
23. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J,
Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized
low density lipoproteins and von Willebrand factor in chronic renal
failure. Thromb Haemost. 1996;76:663–669.
24. Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A,
Imanaka T, Takano T. Oxidized phosphatidylcholines that modify
proteins. Analysis by monoclonal antibody against oxidized low density
lipoprotein. J Biol Chem. 1996;271:33208–33217.
25. Sundstrom C, Nilsson K. Establishment and characterization of a human
histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17:565–577.
26. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation
of antiphospholipid antibody recognition with the structure of synthetic
oxidized phospholipids. Importance of Schiff base formation and aldol
concentration. J Biol Chem. 2002;277:7010–7020.
27. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T,
Takano T. A monoclonal antibody against oxidized lipoprotein rec-
ognizes foam cells in atherosclerotic lesions. Complex formation of
oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269:
15274–15279.
28. Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound
to aggregated C- reactive protein: possible mechanism of foam-cell for-
mation in atherosclerotic lesions. Biochem J. 2002;366:195–201.
29. Chang MK, Boullier A, Almazan F, Quehenberger O, Witztum JL.
C-reactive protein inhibits macrophage binding of oxidized LDL. Arte-
rioscler Thromb Vasc Biol 2003;23:a-74. Abstract.
30. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W,
Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein fre-
quently colocalizes with the terminal complement complex in the intima
of early atherosclerotic lesions of human coronary arteries. Arterioscler
Thromb Vasc Biol. 1998;18:1386–1392.
31. Reynolds GD, Vance RP. C-reactive protein immunohistochemical local-
ization in normal and atherosclerotic human aortas. Arch Pathol Lab Med.
1987;111:265–269.
32. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohisto-
chemical localization of C-reactive protein-binding sites in human ath-
erosclerotic aortic lesions by a modified streptavidin-biotin-staining
method. Pathol Int. 1995;45:635–641.
33. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of
phosphatidylserine-catalyzed inflammation and coagulation during apo-
ptosis. Cell Mol Life Sci. 1997;53:527–532.
34. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel
assay for apoptosis. Flow cytometric detection of phosphatidylserine
expression on early apoptotic cells using fluorescein labelled Annexin V.
J Immunol Methods. 1995;184:39–51.
35. Leitinger N. Oxidized phospholipids as modulators of inflammation in
atherosclerosis. Curr Opin Lipidol. 2003;14:421–430.
722 Arterioscler Thromb Vasc Biol. April 2005
 at Radboud Universiteit Nijmegen on December 4, 2012http://atvb.ahajournals.org/Downloaded from 
